2026-04-25T15:04:38Z https://www.pub.unibl.org/oai

oai:pub.unibl.org:21494 2025-12-19T04:43:59Z

Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57. /unibl/author/Jelena Rožić https://www.unibl.org/sr-lat/fis/zaposlen/3371-zdenka-gojkovic /unibl/author/S Jungić /unibl/author/Ivanka Rakita /unibl/author/Ž Vranješ /unibl/author/R Rašeta /unibl/author/G Marić /unibl/author/M Vještica /unibl/author/S Mijatović /unibl/author/Predrag Dašić /unibl/author/M Vižin J. Rožić, Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57., This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011., 2011. 2011 Article text /unibl/sci/idNaucniRad:8551 This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011. https://www.pub.unibl.org/s/cir/item/21494